CHJT.F 주식 개요 투자 지주 회사인 CSPC 제약 그룹은 중화인민공화국, 기타 아시아 지역, 북미, 유럽 및 국제적으로 의약품의 연구 개발, 제조 및 판매에 종사하고 있습니다. 자세한 내용
생각, 링크 및 회사 내러티브를 캡처하세요.
CSPC Pharmaceutical Group Limited 경쟁사 가격 내역 및 성능
다음에 대한 주가 최고가, 최저가 및 변동 요약 CSPC Pharmaceutical Group 과거 주가 현재 주가 HK$0.59 52주 최고치 HK$0.96 52주 최저치 HK$0.54 베타 0.64 1개월 변경 -11.70% 3개월 변경 사항 -4.49% 1년 변경 사항 n/a 3년 변화 -41.83% 5년 변화 -73.11% IPO 이후 변화 64.33%
최근 뉴스 및 업데이트 CSPC Pharmaceutical Group Limited Announces SYS6005 (Antibody-Drug Conjugate) Obtains Clinical Trial Approval
CSPC Pharmaceutical Group Limited Announces Board Changes Dec 06
CSPC Pharmaceutical Group Limited to Report Nine Months, 2024 Results on Nov 15, 2024 Nov 06 CSPC Pharmaceutical Group Limited Announces Omalizumab for Injection Obtains Marketing Approval from NMPA
CSPC Pharmaceutical Group Limited Announces Valsartan Levoamlodipine Maleate Tablets Obtains Clinical Trial Approval Sep 20 CSPC Pharmaceutical Group Limited (SEHK:1093) announces an Equity Buyback for HKD 5,000 million worth of its shares. Sep 19
더 많은 업데이트 보기 CSPC Pharmaceutical Group Limited Announces SYS6005 (Antibody-Drug Conjugate) Obtains Clinical Trial Approval
CSPC Pharmaceutical Group Limited Announces Board Changes Dec 06
CSPC Pharmaceutical Group Limited to Report Nine Months, 2024 Results on Nov 15, 2024 Nov 06 CSPC Pharmaceutical Group Limited Announces Omalizumab for Injection Obtains Marketing Approval from NMPA
CSPC Pharmaceutical Group Limited Announces Valsartan Levoamlodipine Maleate Tablets Obtains Clinical Trial Approval Sep 20 CSPC Pharmaceutical Group Limited (SEHK:1093) announces an Equity Buyback for HKD 5,000 million worth of its shares. Sep 19
CSPC Pharmaceutical Group Limited Announces Aprepitant Injection Obtains Drug Registration Approval
CSPC Pharmaceutical Group Limited Declares Interim Dividend for the Six Months Ended 30 June 2024, Payable on 20 November 2024 Aug 21
CSPC Pharmaceutical Group Limited to Report First Half, 2024 Results on Aug 21, 2024 Aug 09
CSPC Pharmaceutical Group Limited Obtains Approval from the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China Jul 11 CSPC Pharmaceutical Group Limited Announces Enlonstobart Injection Obtains Conditional Marketing Approval
CSPC Pharmaceutical Group Limited Obtains Approval from National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China Jun 25 CSPC Pharmaceutical Group Limited Approves Final Dividend for the Year Ended December 31, 2023
CSPC Pharmaceutical Group Limited Announces Recombinant Fully Human Anti-bKlotho Monoclonal Antibody Drug (JMT202) Obtains Approval from National Medical Products Administration of the People's Republic of China May 18
CSPC Pharmaceutical Group Limited to Report Q1, 2024 Results on May 27, 2024 May 16
Cspc Pharmaceutical Group Limited Announces That the Peramivir Injection (15Ml:0.15G) (The "Product") Developed by the Group Has Obtained Drug Registration Approval Granted by the National Medical Products Administration of the People's Republic of China, and Is Deemed to Have Passed the Consistency Evaluation of Quality and Efficacy for Generic Drugs May 15
CSPC Pharmaceutical Group Limited Proposes Final Dividend for the Year Ended 31 December 2023 Apr 28
CSPC Pharmaceutical Group Limited Announces Highly Selective Mat2A Inhibitor (SYH2039) Obtains Clinical Trial Approval in the U.S Apr 27
CSPC Pharmaceutical Group Limited Announces Dapagliflozin Tablets Obtains Drug Registration Approval Mar 23 CSPC Pharmaceutical Group Limited, Annual General Meeting, May 28, 2024
CSPC Pharmaceutical Group Limited Proposes Ordinary Final Cash Dividend for the Year Ended 31 December 2023, Payable on 26 June 2024 Mar 20
CSPC Pharmaceutical Group Limited to Report Fiscal Year 2023 Results on Mar 20, 2024 Mar 09
CSPC Pharmaceutical Group Limited's Bispecific Fusion Protein Drug JMT106 Obtains Clinical Trial Approval from the U.S. Food and Drug Administration Jan 15
CSPC Pharmaceutical Group Limited Announces Submission of New Drug Application for Irinotecan Liposome Injection to U.S. FDA Dec 18
CSPC Pharmaceutical Group Limited Obtains Approval for Dextromethorphan Hydrobromide and Quinidine Sulphate Orally Disintegrating Tablets Dec 12
CSPC Pharmaceutical Group Limited Announces Bivalent Covid-19 MRNA Vaccine (SYS6006.32) Included for Emergency Use in China Dec 02
CSPC Pharmaceutical Group Limited Obtains Approval by the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China Nov 29
CSPC Pharmaceutical Group Limited Obtains Approval by the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China Nov 28
CSPC Pharmaceutical Group Limited to Report Nine Months, 2023 Results on Nov 30, 2023 Nov 21
CSPC Pharmaceutical Group Limited's ALMB-0166 Obtains Approval by the National Medical Products Administration of the People's Republic of China to Conduct Phase II Clinical Trial Evaluating its Efficacy and Safety in Patients with Acute Ischemic Stroke in China Nov 18
Alphamab Oncology and CSPC Pharmaceutical Group Co., Ltd. Jointly Receive Breakthrough Therapy Designation on KN026 by CDE Nov 08
CSPC Pharmaceutical Group Limited Obtains Approval Granted by the National Medical Products Administration of the People's Republic of China Nov 04
CSPC Pharmaceutical Group Limited Obtains Clinical Trial Approval Oct 31
CSPC Pharmaceutical Group Limited Announces NBL-028 for the Treatment of Advanced Tumors Oct 26
CSPC Pharmaceutical Group Limited Announces Biologic License Application Approval for Narlumosbart for Injection (JMT103) by the NMPA Sep 07
CSPC Pharmaceutical Group Limited Announces Semaglutide Injection Obtains Clinical Trial Approval Aug 30
CSPC Pharmaceutical Group Limited Obtains Drug Registration Approval Granted by the National Medical Products Administration of the People's Republic of China Aug 25
CSPC Pharmaceutical Group Limited Declares Interim Dividend for the Six Months Ended 30 June 2023, Payable on 12 October 2023 Aug 24
CSPC Pharmaceutical Group Limited to Report First Half, 2023 Results on Aug 23, 2023 Aug 12
Cspc Pharmaceutical Group Limited Announces Biologic License Application of Batoclimab (Hbm9161) Jun 30
CSPC Ouyi Pharmaceutical Co., Ltd. Obtains Drug Registration Approval Granted by the National Medical Products Administration of the People's Republic of China Jun 27 CSPC Pharmaceutical Group Limited Obtains Clinical Trial Approval Granted by the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China
Cspc Pharmaceutical Group Limited Announces That Clinical Trial Application for Cpo301 Jun 09
Elevation Oncology Inc. Together with CSPC Pharmaceutical Group Limited Announce Promising Initial Clinical Data for SYSA1801 (EO-3021) from the Ongoing Phase 1 Dose Escalation and Expansion Study in China Jun 07
Elevation Oncology Highlights First-In-Human Phase 1 Sysa1801 (Eo-3021) Clinical Data to Be Presented by Partner Cspc Pharmaceutical Group Limited At Asco 2023 Jun 06
CSPC Pharmaceutical Group Limited Declares Final Dividend for the Year Ended 31 December 2022 Jun 01
CSPC Pharmaceutical Group Limited to Report Q1, 2023 Results on May 25, 2023 May 17
CSPC Pharmaceutical Group Limited Announces Highly Selective PRMT5 Inhibitor SYH2045 Obtains Clinical Trial Approval Jan 05
Cspc Pharmaceutical Group Limited Announces ALMB-0166 for the Treatment of Osteoarthritis Obtains Clinical Trial Approval Dec 31
CSPC Pharmaceutical Group Limited Receives Approval for SYH2043 from National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China Dec 30
CSPC Pharmaceutical Group Limited Announces NBL-020 for the Treatment of Advanced Solid Tumors Obtains Clinical Trial Approval in the U.S Dec 23
Cspc Pharmaceutical Group Limited Announces That Syh2055 Developed by the Group Has Obtained Approval Granted by the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China Dec 08
CSPC Pharmaceutical Group Limited Announces Antibody-Drug Conjugate CPO204 Obtains Clinical Trial Approval in the U.S Nov 30
CSPC Pharmaceutical Group Limited's SYHX1901 Tablets Obtains Approval Granted by the National Medical Products Administration Nov 24
CSPC Pharmaceutical Group Limited Announces New Indication Application for Marketing Approval of Mingfule Nov 17
CSPC Pharmaceutical Group Limited to Report Nine Months, 2022 Results on Nov 23, 2022 Nov 12
CSPC Pharmaceutical Group Limited Appoints Li Quan as an Independent Non-Executive Director Nov 09
CSPC Pharmaceutical Group Limited Announces the Antibody-Drug Conjugate Sys6002 Oct 28
CSPC Pharmaceutical Group Limited Announces TG103 Injection Obtains Clinical Trial Approval for the Treatment of Non-Alcoholic Steatohepatitis Sep 10
CSPC Pharmaceutical Group Limited Declares Interim Dividend for the Six Months Ended 30 June 2022, Payable on 11 October 2022 Aug 25
CSPC Pharmaceutical Group Limited Announces Completion of Clinical Study of Heterologous Booster Immunization of SARS-CoV-2 mRNA Vaccine Aug 24
Cspc Pharmaceutical Group Limited Announces Selective Ntrk and Ros1 Dual Inhibitor Syhx2009 Obtains Clinical Trial Approval Aug 23
CSPC Pharmaceutical Group Limited Obtains Drug Registration Approval Granted by the National Medical Products Administration of the People's Republic of China Aug 20
Cspc Pharmaceutical Group Limited Obtains Duoenda (Mitoxantrone Hydrochloride Liposome Injection) Clinical Trial Approval for the Treatment of Neuromyelitis Optica Spectrum Disorders Aug 19
CSPC Pharmaceutical Group Limited to Report First Half, 2022 Results on Aug 24, 2022 Aug 13
CSPC Pharmaceutical Group Announces Resignation of Wu Guizhen as Independent Non-Executive Director Aug 02
CSPC Pharmaceutical Group Limited Announce Biologic License Application for Jmt103 Accepted by the NMPA Jun 23 CSPC Pharmaceutical Group Limited Announces Change of CEO
CSPC Pharmaceutical Group Limited Approves Final Dividend for the Year Ended 31 December 2021 May 27
CSPC Pharmaceutical Group Limited to Report Q1, 2022 Results on May 25, 2022 May 14 CSPC Pharmaceutical Group Limited, Annual General Meeting, May 26, 2022
CSPC Pharmaceutical Group Limited Announces COVID-19 mRNA Vaccine "SYS6006" Obtains Clinical Trial Approval Apr 04
CSPC Pharmaceutical Group Limited (SEHK:1093) acquired 51% stake in Guangzhou Recomgen Biotech Co., Ltd. Feb 09
CSPC Pharmaceutical Group Limited Announces JMT601 (CPO107) Granted Fast Track Designation by U.S. FDA for Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Jan 28
Alphamab Oncology and CSPC Pharmaceutical Group Co., Ltd. Announce Approval of IND Application for Pivotal Clinical Study of HER2 Bispecific Antibody KN026 Combined with Chemotherapy in Gastric Cancer Jan 06
CSPC Pharmaceutical Group Limited Obtains Approval for SYHX2001 Dec 30
CSPC Pharmaceutical Group Limited Announces First Patient Dosed in the Phase 1/2 Clinical Trial of JMT601 in the U.S Dec 15
CSPC Pharmaceutical Group Limited Announces That "Sysa1801" Has Obtained Approval Granted by the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China Jun 17
CSPC Pharmaceutical Group Limited Obtains Approvals for SYHX1903 May 27
CSPC Pharmaceutical Group Limited announces NBL-015 Obtains Clinical Trial Approval in the U.S May 26
CSPC Pharmaceutical Group Limited Announces Innovative Drug "Syha1811 Tablets" Obtains Clinical Trial Approval in China May 21
CSPC Pharmaceutical Group Limited Approves Final Dividend for the Year Ended 31 December 2020 May 19
CSPC Pharmaceutical Group Limited Announces Dual Inhibitor Jak-Syk "Syhx1901" Obtains Clinical Trial Approval Mar 17 Cspc Pharmaceutical Group Limited Recommends a Final Dividend for the Year Ended 31 December 2020, Payable on 11 June 2021
CSPC Pharmaceutical Group Limited Announces Directorate Changes, Effective March 8, 2021 Mar 07 주주 수익률 CHJT.F US Pharmaceuticals US 마켓 7D -9.0% 0.6% -0.4% 1Y n/a 10.0% 24.8%
전체 주주 수익률 보기
수익률 대 산업: US Pharmaceuticals 산업에 대해 CHJT.F 의 성과를 판단하기에는 데이터가 부족합니다.
수익률 대 시장: US 시장에 대해 CHJT.F 의 성과를 판단하기에는 데이터가 부족합니다.
가격 변동성 Is CHJT.F's price volatile compared to industry and market? CHJT.F volatility CHJT.F Average Weekly Movement n/a Pharmaceuticals Industry Average Movement 10.5% Market Average Movement 6.3% 10% most volatile stocks in US Market 17.0% 10% least volatile stocks in US Market 3.1%
안정적인 주가: CHJT.F 의 주가는 지난 3개월 동안 변동성이 심했습니다.
시간에 따른 변동성: 지난 1년간 CHJT.F 의 변동성 변화를 확인하기에는 데이터가 충분하지 않습니다 .
회사 소개 투자 지주 회사인 CSPC 제약 그룹은 중화인민공화국, 기타 아시아 지역, 북미, 유럽 및 국제적으로 의약품의 연구 개발, 제조 및 판매에 종사하고 있습니다. 이 회사는 완제의약품, 벌크 제품, 기능성 식품 및 기타 부문을 통해 사업을 운영하고 있습니다. 급성 허혈성 뇌졸중 치료제인 NBP 연질 캡슐 및 주사제, 경증에서 중등도의 기억력 및 정신 장애를 치료하는 어울링 캡슐 및 주사제, 성인 특발성 파킨슨병 치료제인 엔시, 림프종, 다발성 골수종, 난소암 및 유방암, 기타 악성 종양 치료제인 듀오메이수, 화학요법으로 인한 백혈구 감소증 및 감염 예방제 진율리, 유방암 치료제 케일리를 공급하고 있습니다.
자세히 보기 CSPC Pharmaceutical Group Limited 기본 사항 요약 CSPC Pharmaceutical Group 의 수익과 매출은 시가총액과 어떻게 비교하나요? CHJT.F 기본 통계 시가총액 US$7.17b 수익(TTM ) US$706.84m 수익(TTM ) US$4.15b
수익 및 수익 최신 수익 보고서의 주요 수익성 통계(TTM) CHJT.F 손익 계산서(TTM ) 수익 CN¥30.27b 수익 비용 CN¥8.90b 총 이익 CN¥21.37b 기타 비용 CN¥16.21b 수익 CN¥5.16b
주당 순이익(EPS) 0.44 총 마진 70.59% 순이익 마진 17.04% 부채/자본 비율 1.1%
CHJT.F 의 장기적인 성과는 어땠나요?
과거 실적 및 비교 보기 기업 분석 및 재무 데이터 현황 데이터 마지막 업데이트(UTC 시간) 기업 분석 2024/12/25 13:52 장 마감 주가 2024/12/23 00:00 수익 2024/09/30 연간 수익 2023/12/31
데이터 소스 기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.
패키지 데이터 기간 미국 소스 예시 * 회사 재무 10년 애널리스트 컨센서스 추정치 +3년 시장 가격 30년 소유권 10년 관리 10년 주요 개발 사항 10년
* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.
명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.
분석 모델 및 눈송이 이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.
Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.
산업 및 부문 메트릭 업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.
애널리스트 출처 CSPC Pharmaceutical Group Limited 50 애널리스트 중 27 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.
분석가 교육기관 Wai Chak Yuen BOCI Research Ltd. Sharon Shi BOCI Research Ltd. Ethan Cui BofA Global Research
47 더 많은 분석가 보기 
